GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Zomedica Corp (AMEX:ZOM) » Definitions » Beneish M-Score

Zomedica (Zomedica) Beneish M-Score : -2.50 (As of May. 13, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Zomedica Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.5 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Zomedica's Beneish M-Score or its related term are showing as below:

ZOM' s Beneish M-Score Range Over the Past 10 Years
Min: -2.5   Med: -1.02   Max: 0.47
Current: -2.5

During the past 11 years, the highest Beneish M-Score of Zomedica was 0.47. The lowest was -2.50. And the median was -1.02.


Zomedica Beneish M-Score Historical Data

The historical data trend for Zomedica's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zomedica Beneish M-Score Chart

Zomedica Annual Data
Trend Feb14 Feb15 Feb16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - 0.47 -2.50

Zomedica Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 -1.24 -1.19 -2.12 -2.50

Competitive Comparison of Zomedica's Beneish M-Score

For the Medical Devices subindustry, Zomedica's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Zomedica's Beneish M-Score Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Zomedica's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Zomedica's Beneish M-Score falls into.



Zomedica Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Zomedica for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.8863+0.528 * 1.0347+0.404 * 0.9621+0.892 * 1.3305+0.115 * 1.5351
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9888+4.679 * -0.035561-0.327 * 1.3445
=-2.50

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $2.20 Mil.
Revenue was 7.337 + 6.347 + 6.02 + 5.482 = $25.19 Mil.
Gross Profit was 5.073 + 4.362 + 4.048 + 3.835 = $17.32 Mil.
Total Current Assets was $99.88 Mil.
Total Assets was $253.20 Mil.
Property, Plant and Equipment(Net PPE) was $25.29 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.30 Mil.
Selling, General, & Admin. Expense(SGA) was $43.17 Mil.
Total Current Liabilities was $9.03 Mil.
Long-Term Debt & Capital Lease Obligation was $1.81 Mil.
Net Income was -22.406 + -0.491 + -5.249 + -6.385 = $-34.53 Mil.
Non Operating Income was -11.707 + 2.164 + 0.018 + -0.027 = $-9.55 Mil.
Cash Flow from Operations was -5.015 + -3.027 + -3.676 + -4.257 = $-15.98 Mil.
Total Receivables was $1.86 Mil.
Revenue was 6.157 + 4.776 + 4.246 + 3.751 = $18.93 Mil.
Gross Profit was 4.211 + 3.511 + 3.006 + 2.74 = $13.47 Mil.
Total Current Assets was $123.50 Mil.
Total Assets was $279.61 Mil.
Property, Plant and Equipment(Net PPE) was $9.17 Mil.
Depreciation, Depletion and Amortization(DDA) was $4.04 Mil.
Selling, General, & Admin. Expense(SGA) was $32.81 Mil.
Total Current Liabilities was $7.81 Mil.
Long-Term Debt & Capital Lease Obligation was $1.10 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(2.198 / 25.186) / (1.864 / 18.93)
=0.087271 / 0.098468
=0.8863

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(13.468 / 18.93) / (17.318 / 25.186)
=0.711463 / 0.687604
=1.0347

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (99.882 + 25.294) / 253.197) / (1 - (123.501 + 9.166) / 279.61)
=0.505618 / 0.525528
=0.9621

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=25.186 / 18.93
=1.3305

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(4.042 / (4.042 + 9.166)) / (6.298 / (6.298 + 25.294))
=0.306027 / 0.199354
=1.5351

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(43.166 / 25.186) / (32.812 / 18.93)
=1.713889 / 1.733333
=0.9888

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((1.814 + 9.032) / 253.197) / ((1.097 + 7.811) / 279.61)
=0.042836 / 0.031859
=1.3445

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-34.531 - -9.552 - -15.975) / 253.197
=-0.035561

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Zomedica has a M-score of -2.50 suggests that the company is unlikely to be a manipulator.


Zomedica Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Zomedica's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Zomedica (Zomedica) Business Description

Traded in Other Exchanges
N/A
Address
100 Phoenix Drive, Suite 125, Ann Arbor, MI, USA, 48108
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is currently focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its operations are comprised of two reportable segments: Diagnostic & Therapeutics. It earns the majority of revenue from the therapeutics segment.
Executives
Johnny D Powers director C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Heaton Larry C Ii officer: President C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Russell Kevin Klass officer: Vice President of Sales C/O ZOMEDICA CORP, PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Peter Donato officer: Chief Financial Officer 9172 ETON AVENUE, CHATSWORTH CA 91311
Pamela Nichols director 14841 EAST WILDCAT DR., SCOTTSDALE AZ 85262
Karen Dehaan-fullerton officer: Chief Counsel and Secretary C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Anthony K Blair officer: Chief Operating Officer NEOPROBE CORPORATION, 425 METRO PLACE NORTH #300, DUBLIN OH 43017
Adrian Lock officer: VP and General Manager C/O ZOMEDICA CORP, 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Sean Whelan director C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Robert Cohen officer: Interim CEO C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Ann Cotter officer: Chief Financial Officer & Sec. C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108
Stephanie Morley officer: COO & VP of Product Dev C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48108
Christopher Ross Macleod director C/O ZOMEDICA CORP., 100 PHOENIX DRIVE, SUITE 125, ANN ARBOR MI 48018
Christopher Wolfenberg director C/O ZOMEDICA PHARMACEUTICALS CORP, 100 PHOENIX DRIVE, SUITE 180, ANN ARBOR MI 48108
Gerald Jr Solensky director, 10 percent owner, officer: President and CEO C/O ZOMEDICA PHARMACEUTICALS CORP., 100 PHOENIX DRIVE, SUITE 190, ANN ARBOR MI 48108